Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Altered glutamatergic neurotransmission is implicated in the pathogenesis of major depressive disorder. AXS-05 (dextromethorphan-bupropion) is an oral NMDA receptor antagonist and sigma-1 receptor agonist, which utilizes inhibition of CYP2D6 to increase its bioavailability. This phase 2 trial assessed the efficacy and safety of dextromethorphan-bupropion in the treatment of major depressive disorder. METHODS: This randomized, double-blind, multicenter, parallel-group trial evaluated dextromethorphan-bupropion versus the active comparator sustained-release bupropion in patients 18-65 years old with a diagnosis of major depressive disorder of moderate or greater severity. Patients were randomly assigned to receive either dextromethorphan-bupropion (45 mg/105 mg tablet) or bupropion (105 mg tablet), once daily for the first 3 days and twice daily thereafter, for a total of 6 weeks. The primary endpoint was overall treatment effect on Montgomery-Åsberg Depression Rating Scale (MADRS) score (average of the change from baseline for weeks 1-6), assessed in all randomized patients whose diagnosis and severity were confirmed by an independent assessor and who received at least one dose of study medication and had at least one postbaseline assessment. RESULTS: Of 97 patients randomized, 17 did not have a confirmed diagnosis and severity based on the independent assessment, resulting in 80 patients in the efficacy population (dextromethorphan-bupropion, N=43; bupropion, N=37). The mean change from baseline in MADRS score over weeks 1-6 (overall treatment effect) was significantly greater with dextromethorphan-bupropion than with bupropion (-13.7 points vs. -8.8 points; least-squares mean difference=-4.9; 95% CI=-3.1, -6.8). MADRS score change with dextromethorphan-bupropion was significantly greater than with bupropion at week 2 and every time point thereafter (week 6: -17.3 vs. -12.1 points; least-squares mean difference=-5.2, 95% CI=-1.1, -9.3). Remission rates were significantly greater with dextromethorphan-bupropion at week 2 and every time point thereafter (week 6: 46.5% vs. 16.2%; least-squares mean difference=30.3%, 95% CI=11.2, 49.4). Response rates (≥50% decrease in MADRS score from baseline) at week 6 were 60.5% with dextromethorphan-bupropion and 40.5% with bupropion (least-squares mean difference=19.9%, 95% CI=-1.6, 41). Most secondary outcomes favored dextromethorphan-bupropion. The most common adverse events with dextromethorphan-bupropion were dizziness, nausea, dry mouth, decreased appetite, and anxiety. Dextromethorphan-bupropion was not associated with psychotomimetic effects, weight gain, or sexual dysfunction. CONCLUSIONS: In patients with major depression, dextromethorphan-bupropion (AXS-05) significantly improved depressive symptoms compared with bupropion and was generally well tolerated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Dextromethorphan’s primary potential for MDD treatment is theorized to be due to its uncompetitive antagonism of the ionotropic glutamate receptor NMDA in the central nervous system [17,18].”
From Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder (2023) · cites this paper as [17]
In the citing paper
“Remission and response rates were significantly higher with dextromethorphan-bupropion in both studies.”
From Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder (2023) · cites this paper as [17]
In the citing paper
“The medication was well-tolerated in both trials, with the most common adverse events being rated as mild-to-moderate.”
From Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder (2023) · cites this paper as [17]
In the citing paper
“Changes in Montgomery–Åsberg Depression Rating Scale with dextromethorphan-bupropion were seen within two weeks in both clinical trials.”
From Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder (2023) · cites this paper as [17]
In the citing paper
“Dextromethorphan-bupropion was assessed for efficacy and safety in treating major depressive disorder (MDD) in a phase 2, randomized, double-blind, active-controlled trial (n = 80) [17].”
From Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder (2023) · cites this paper as [17]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109
Fava, M., & Kendler, K. S. (2000) · Neuron · doi:10.1016/s0896-6273(00)00112-4 · Cited by 603
Fava, M., Evins, A. E., Dorer, D. J., & Schoenfeld, D. A. (2003) · Psychotherapy and Psychosomatics · doi:10.1159/000069738 · Cited by 452
The Impact of Treatment-Resistant Depression on Health Care Utilization and Costs
Crown, W. H., Finkelstein, S., Berndt, E. R., Ling, D., Poret, A. W., Rush, A. J., & Russell, J. M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1102 · Cited by 386
Pharmacology and Therapeutic Potential of Sigma1 Receptor Ligands
Cobos, E., Entrena, J., Nieto, F., Cendan, C., & Pozo, E. (2008) · Current Neuropharmacology · doi:10.2174/157015908787386113 · Cited by 376
Research works printed but not linked: 7
- Saltiel PF, 2015, Neuropsychiatr Dis Treat, 11, 875
- World Health Organization, 2018, Fact Sheets: Depression
- Whitlock ME, 2019, Innov Clin Neurosci, 16, 12
- International Conference on Harmonisation, 2001, J Postgrad Med, 47, 45
- First MB, 2015, Structured Clinical Interview for DSM-5 Disorders Clinical Trials Version (SCID-5-CT)
- Davidson JR, 1998, J Clin Psychiatry, 59, 25
- Keefe RS, 2013, Innov Clin Neurosci, 10, 4S
Cited by
Items 101–140 of 140
Protein misfolding and neurodegeneration: Mechanisms, implications, and therapeutic strategies
Shah, A., Karthikeyan, T., Hashem, S., Kumar, R., Bhat, A. A., & Macha, M. A. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2025.08.012 · Cited by 2
Advancing depression treatment: the role of sigma receptor ligands
Zhang, P., Ning, Z., Chen, H., Chen, J., Lu, Z., & Xu, F. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1691987 · Cited by 1
Advances in antidepressant pharmacotherapy: phase 3 evidence and clinical perspectives
Cuomo, A., Pinzi, M., & Fagiolini, A. M. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2634195 · Cited by 1
“Furthermore, results from an active-comparator trial indicated that AXS-05 was more effective than bupropion alone in reducing depressive symptoms, supporting a synergistic contribution of the two components [37].”
Kittirattanapaiboon, C., Shoptaw, S., Mayes, T., Jha, M., Ghitza, U., & Trivedi, M. (2026) · Journal of substance use and addiction treatment · doi:10.1016/j.josat.2026.209994 · Cited by 1
Regen, F. (2026) · Springer eBooks · doi:10.1007/978-3-662-72452-1_1 · Cited by 1
Considerations on combination therapies for disease modification in Parkinson’s
Hughes, R. M., Pilcicka, A., Klee, T., Ducotterd, F., Mortiboys, H., & Stott, S. (2026) · npj Parkinson s Disease · doi:10.1038/s41531-026-01483-9 · Cited by 1
Ongoing phase 2/3 trials of psychotropic drugs: is help finally on the way?
Thase, M. E. (2023) · World Psychiatry · doi:10.1002/wps.21064 · Cited by 1
Chen, M., & Tsai, S. (2023) · Medical Hypotheses · doi:10.1016/j.mehy.2023.111242 · Cited by 2
Potential therapeutic strategies to halt viral neuroinvasion
Zhang, L., Ashraf, U., Chen, H., Cao, S., & Ye, J. (2024) · Reviews in Medical Virology · doi:10.1002/rmv.2539 · Cited by 1
“60 Alter-natively, NMDAR antagonists, such as the FDA ‐ approved dextro-methorphan HBr ‐ bupropion HCl (AXS ‐ 05) against major depressive disorder in adults, 61,62 may also ameliorate such neurotoxicity by CCL2.”
BackgroundCase report: Dezocine’s rapid and sustained antidepressant effects
Wang, H., Lyu, N., & Zhao, Q. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1411119 · Cited by 1
Woodard, D. F., Boyle, L., & Zwiebel, S. J. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002034 · Cited by 1
Ngo, S., Rine, N. I., Kistamgari, S., Smith, G. A., & Hays, H. L. (2025) · Toxicology Communications · doi:10.1080/24734306.2025.2530331 · Cited by 1
“There are limited data on the toxicity of DXM-BUP, and most of the adverse effects related to DXM-BUP have been described in clinical trial settings [9,14–16].”
Zhao, K., & Liu, J. (2025) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2025.104657 · Cited by 1
Hypomanic Switch Induced by Dextromethorphan–Bupropion Combination: A Case Report
Aggarwal, M., Singh, J., & Udey, B. (2025) · Indian Journal of Psychological Medicine · doi:10.1177/02537176251387989 · Cited by 1
Loganin exerts antidepressant-like effects via Sigma-1R- and BDNF-dependent mechanismsPreprint
Xia, C., Wang, Y., Wang, M., Guo, Y., Lian, W., Yu, Y., Ma, B.-Z., Xu, J., He, J., & Zhang, W. (2023) · doi:10.22541/au.167646432.21834488/v1
Neuroscientific Advances Supporting New Treatments for Major Depression
Kalin, N. H. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20220445
Alnaher, S., Alramahi, M., Arida, A. K., & Arida, A. (2023) · Cognizance Journal of Multidisciplinary Studies · doi:10.47760/cognizance.2023.v03i10.028
Stahl, S. M. (2024) · Prescriber's Guide · doi:10.1017/9781009464772.038
Pharmacological Approaches to Depression and Treatment-Resistant Depression
Fava, M., Baek, J. H., Nierenberg, A. A., Mischoulon, D., Cusin, C., Cassano, P., & Papakostas, G. I. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-11844-9.00051-5
(2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894551289.cd03 · Cited by 1
Gillespie, C. F., & Nemeroff, C. B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19176-3.00046-7
Pharmacological Approaches to Depression and Treatment-Resistant Depression
Fava, M., Baek, J. H., Nierenberg, A. A., Mischoulon, D., Cusin, C., Cassano, P., & Papakostas, G. I. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-11972-9.00003-x
Pompili, M., Berardelli, I., Erbuto, D., & Caraci, F. (2025) · Annals of General Psychiatry · doi:10.1186/s12991-025-00549-x · Cited by 1
“Tabuteau et al. [56], in a randomized, double-blind, multicenter, parallel-group study on patients diagnosed with moderate or severe MDD, compared dextromethorphan-bupropion to the active comparator sustained-release bupropion.”
Effects of antidepressants on weight: mechanisms, clinical effects, and management strategies
Bairamalov, V. A., Dautova, V. A., Bakhareva, M. D., Mariams, A. S. Z., Alyeva, L. R., Ismikhanov, M. M., Gazizova, A. I., Zorina, N. A., Malinina, Y. A., Vedernikova, V. V., et al. (2025) · Russian Medicine · doi:10.17816/medjrf675281
Recent advances in rapid-acting antidepressants
Pan, L., He, Y., Wang, G., & Shen, J. (2025) · Scientia Sinica Chimica · doi:10.1360/ssc-2025-0157
Zheng, Y. J., Dri, C. E., Wong, S., Le, G. H., Teopiz, K. M., Kwan, A. T. H., & McIntyre, R. S. (2025) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2025.2607017
“Further evidence positions DXM/BUP usage as having reduced association with abuse, weight gain, and/or psychotomimetic outcomes [12,13].”
Aggarwal, M., Singh, J., Kaur, K., Thakur, M., & Guleria, R. (2026) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry_979_25 · Cited by 1
“[7,8] Importantly, bupropion inhibits CYP2D6, thereby increasing the oral bioavailability of dextromethorphan, and prolonging its antidepressant action.”
Cheung, N. (2026) · Cureus · doi:10.7759/cureus.105367
“…responsible for O-demethylation of dextromethorphan to its less centrally active metabolite dextrorphan -- to keep dextromethorphan active and has shortened onset times in major depressive disorder [7], though its value for OCD-spectrum conditions, including hypochondriacal OCD, is still uncertain.”
Riestra, J. M., Levin-Carrion, Y., Sutar, R. F., Mitchell, J., Jambulingam, P., Ballaz, S., Shad, M. U., Rahman, S., Barlati, S., & Koola, M. M. (2026) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.70039 · Cited by 1
“While the ASEND and the GEMINI trials both reported statistically significant differences favoring BDC, the actual MADRS improvements were only 5.2 and 3.9 points, respectively, which were greater than those with bupropion (Iosifescu et al. 2022; Tabuteau et al. 2022).”
InfluentialDuncan, E., Hersant, H., & Khairova, R. A. (2026) · Springer eBooks · doi:10.1007/978-3-032-15772-0_4
Carmellini, P., Cuomo, A., Rescalli, M. B., Pinzi, M., Dourmas, A., & Fagiolini, A. M. (2026) · Pharmaceuticals · doi:10.3390/ph19050662 · Cited by 1
Thulasingam, M., & Vellapandian, C. (2026) · Current Drug Therapy · doi:10.2174/0115748855435564251207185418
Bu, F., Qin, L., Zi-yang, L. O. U., Xie, Y., Zhang, S. Z., Xiong, L., & Wen, Y. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s609327
“22,23”
Chapter 47. Pharmacological Treatments in Development
Pham, G. S., & Mathew, S. J. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894551920.lg47
Wang, H., Liao, W., Li, Y., Guo, A., Liu, Z., Guo, X., Wang, K., Zheng, Y., Wang, Z., Wang, W., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03830
Yakovleva, O. B., Сафарова, Т. П., & Savushkina, O. K. (2026) · Psikhiatriya · doi:10.30629/2618-6667-2026-24-2-15-27
Liu, R., Liu, C., Li, C., Hu, D., Wang, L., Li, Z. J., Feng, D., & Guo, T. (2026) · Medicine · doi:10.1097/md.0000000000049464
“[32] The most common AEs included dizziness, nausea, headache, somnolence, and dry mouth in the phase 3 trial.”
Clayton, A. H., Alva, G., Bowman, P., Crown, E., Das, B., Doghramji, P. P., Kempf, B., Muzyk, A. J., Schreiber, J., & Miller, J. J. (2026) · Current Medical Research and Opinion · doi:10.1080/03007995.2026.2700073
“Dextromethorphan-bupropion extended release (45 mg/105 mg) (AUVELITY; Axsome Therapeutics, Inc., NY, USA) is an oral N-methyl-D-aspartate receptor (NMDA-R) antagonist and sigma-1 receptor agonist approved for the treatment of MDD in adults 11–15 .”
Kavuran, İ. B., Önalan, E., Turk, Z. I., & Eröksüz, H. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1910199
“This behavioral pattern is consistent with clinical findings demonstrating early symptom improvement with the dextromethorphan–bupropion combination (Iosifescu, 2022b; Tabuteau, 2022b).”
Citrome, L., Zhao, Y., Zeni, C. M., Princic, N., Richards, M., Alter, S. P., & Cutler, A. J. (2026) · Journal of Medical Economics · doi:10.1080/13696998.2026.2746279
Metadata
- Authors
- Tabuteau, H., Jones, A., Anderson, A., Jacobson, M., & Iosifescu, D. V.
- Affiliations
- Axsome Therapeutics (United States) (US)
- ORCID
- Iosifescu, Dan V.
- Venue
- American Journal of Psychiatry
- Published
- 2022-07-01
- Volume
- 179
- Issue
- 7
- Pages
- 490-499
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W4280521929
- Cited by
- 140
- References
- 31
- Citations by year
- 2026: 22 · 2025: 37 · 2024: 33 · 2023: 34 · 2022: 14
- FWCI
- 17.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacological Receptor Mechanisms and Effects
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- major depressive disorder, NMDA receptor antagonists, sigma-1 receptor agonist, bupropion, CYP2D6 inhibition, glutamatergic neurotransmission, antidepressant efficacy, remission, treatment safety, adverse events, antidepressant drug development
- MeSH terms
- Adolescent, Adult, Aged, Major Depressive Disorder, Depressive Disorder, Major, Dextromethorphan, Double-Blind Method, Humans, Middle Aged, Bupropion, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.